ContraFect Corp.
OTC: CFRXQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Roger J. Pomerantz
- Employees
- 23
- Headquarters
- Yonkers, United States
- IPO year
- 2014
- Market cap
- $107.0
- Website
- https://www.contrafect.com
Loading CFRXQ…
Loading profile data…Frequently asked questions about CFRXQ
What does ContraFect Corp. (CFRXQ) do?
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
Where does CFRXQ trade?
ContraFect Corp. (CFRXQ) trades on the Other OTC.
What sector is CFRXQ in?
ContraFect Corp. (CFRXQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ContraFect Corp.?
Roger J. Pomerantz is the chief executive officer of ContraFect Corp. (CFRXQ).
Where is ContraFect Corp. headquartered?
ContraFect Corp. is headquartered in United States.
Does CFRXQ pay a dividend?
ContraFect Corp. (CFRXQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CFRXQ go public?
ContraFect Corp. (CFRXQ) completed its initial public offering in 2014.